Positive 16-Week Findings Highlighted on Tralokinumab for Atopic Dermatitis on the Hands

LEO Pharma reports results from interim analysis of Phase IIIb atopic dermatitis trial

LEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).The post LEO Pharma reports results from interim analysis of Phase IIIb atopic dermatitis trial appeared first on Clinical Trials Arena.

Tralokinumab Shows Hand Relief in ADHAND Trial

LEO Pharma reveals promising interim results for tralokinumab in treating moderate to severe atopic dermatitis on hands, enhancing patient quality of life.

Positive 16-Week Findings Highlighted on Tralokinumab for Atopic Dermatitis on the Hands

These ADHAND trial data highlight the results of tralokinumab in those with atopic dermatitis on the hands who are candidates for systemic therapy.